Breakthrough in Obesity Treatment: FDA Approves Oral Version of Wegovy
The U.S. Food and Drug Administration (FDA) has given the green light to a pill version of the popular weight-loss drug Wegovy, marking a significant milestone in the treatment of obesity. This daily oral medication is the first of its kind to be approved for obesity treatment, offering a more convenient and potentially more accessible alternative to injectable treatments.
Novo Nordisk, the manufacturer of Wegovy, has gained an edge over its rival Eli Lilly, whose oral drug orforglipron is still under review. Both pills belong to the GLP-1 class of drugs, which mimic a natural hormone that regulates appetite and feelings of fullness. The injectable versions of these drugs, such as Wegovy and Zepbound, have revolutionized obesity treatment globally and in the U.S., where approximately 100 million people suffer from the chronic disease.
Expert Insights and Clinical Trial Results
According to Dr. Reshmi Srinath, director of the Mount Sinai Weight and Metabolism Management Program in New York, “having an oral option would be really helpful, not only for improving access but also as another tool that we can offer patients.” Dr. Fatima Cody Stanford, a Massachusetts General Hospital obesity expert, adds, “There’s an entire demographic that can benefit from the pills. For me, it’s not just about who gets it across the finish line first. It’s about having these options available to patients.”
In a clinical trial, participants who took oral Wegovy lost an average of 13.6% of their total body weight over approximately 15 months, compared to a 2.2% loss for those who took a placebo. This is nearly equivalent to the average weight loss achieved with injectable Wegovy, which is around 15%. Chris Mertens, a 35-year-old pediatric lung doctor, participated in the Novo Nordisk trial and lost about 40 pounds using the Wegovy pill, citing its effectiveness in decreasing his appetite and intrusive thoughts about food.
Side Effects, Cost, and Accessibility
Both oral and injectable GLP-1 drugs have similar side effects, including nausea and diarrhea. The Wegovy pill must be taken with a sip of water on an empty stomach, with a 30-minute break before eating or drinking, due to its design to prevent breakdown in the stomach. In contrast, Lilly’s orforglipron has no dosing restrictions.
The cost of the Wegovy pill is expected to be lower than that of injectable treatments, with a starting dose available for $149 per month from some providers. Producing pills is generally cheaper than making injectable drugs, which can cost upwards of $1,000 per month. Dr. Angela Fitch, an obesity expert and chief medical officer of Knownwell, emphasizes that the biggest benefit will be in making weight-loss medications more widely accessible and affordable, stating, “It’s all about the price. Just give me a drug at $100 a month that is relatively effective.”
Conclusion and Future Directions
The FDA’s approval of the oral version of Wegovy marks a significant step forward in the treatment of obesity. As the first daily oral medication approved for obesity treatment, it offers a more convenient and potentially more accessible alternative to injectable treatments. With its expected lower cost and equivalent effectiveness, the Wegovy pill is poised to expand the booming market for obesity treatments and improve access to care for millions of Americans. For more information, visit Here
Image Source: www.cbsnews.com
